Searching for Reliable Epidermal Growth Factor Receptor Response Predictors

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 428-432

  Harari, Paul M ^a   Huang, Shyh Min ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANERTINIB; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PELITINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; STAT PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENOMICS; HEAD AND NECK CANCER; HUMAN; IMAGING; LUNG NON SMALL CELL CANCER; NONHUMAN; NOTE; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; RADIOSENSITIVITY; RECEPTOR DOWN REGULATION;

CELL LINE, TUMOR; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0842268395     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1220-03     Document Type: Note

References (44)

1. Cohen, S. The epidermal growth factor (EGF). Cancer (Phila.), 51: 1787-1791, 1983.
2. Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J., Polikoff, J., and Sato, G. H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med., 1: 511-529, 1983.
3. Mendelsohn, J., and Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene, 19: 6550-6565, 2000.
4. de Bono, J. S., and Rowinsky, E. K. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med., 8: S19-S26, 2002.
5. Arteaga, C. Targeting HERI/EGFR: a molecular approach to cancer therapy. Semin. Oncol., 30: 3-14, 2003.
6. Seymour, L. Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics. Curr. Opin. Investig. Drugs, 4: 658-666, 2003.
7. Baselga, J. Current and planned clinical trials with trastuzumab (Herceptin). Semin. Oncol., 27: 27-32, 2000.
8. Nyati, M. K., Maheshwari, D., Hanasoge, S., Sreekumar, A., Rynkiewicz, S. D., Chinnaiyan, A. M., Leopold, W. R., Eithier, S. P., and Lawrence, T. S. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004.
9. Huang, S-M., Bock, J. M., and Harari, P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res., 59: 1935-1940, 1999.
10. Saleh, M. N., Raisch, K. P., Stackhouse, M. A., Grizzle, W. E., Bonner, J. A., Mayo, M. S., Kim, H. G., Meredith, R. F., Wheeler, R. H., and Buchsbaum, D. J. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother. Radiopharm., 14: 451-463, 1999.
11. Raben, D., Buchsbaum, D. J., Gillespie, Y., Randall, S., Saleh, M., and Waksal, H. Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation. Proc. Am. Assoc. Cancer Res., 40: 184, 1999.
12. Huang, S-M., and Harari, P. M. Modulation of radiation response following epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin. Cancer Res., 6: 2166-2174, 2000.
13. Milas, L., Mason, K., Hunter, N., Petersen, S., Yamakawa, M., Ang, K., Mendelsohn, J., and Fan, Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res., 6: 701-708, 2000.
14. Rao, G. S., Murray, S., and Ethier, S. P. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int. J. Radiat. Oncol. Biol. Phys., 48: 1519-1528, 2000.
15. Huang, S-M., Li, J., Armstrong, E. A., and Harari, P. M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res., 62: 4300-4306, 2002.
16. Williams, K. J., Telfer, B. A., Stratford, I. J., and Wedge, S. R. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br. J. Cancer, 86: 1157-1161, 2002.
17. Chakravarti, A., Chakladar, A., Delaney, M. A., Latham, D. E., and Loeffler, J. S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res., 62: 4307-4315, 2002.
18. Bianco, C., Tortora, G., Bianco, R., Caputo, R., Veneziani, B. M., Caputo, R., Damiano, V., Troiani, T., Fontanini, G., Raben, D., Pepe, S., Bianco, A. R., and Ciardiello, F. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res., 8: 3250-3258, 2002.
19. Nakata, E., Raju, U., Hunter, N. R., Mason, K. A., Fan, Z., Ang, K. K., Yamada, S., and Milas, L. C225, an anti-EGFR antibody, enhances radiosensitivity of MDA468 cancer cells: possible role of cell-cycle arrest and inhibition of AP-1 transcription factor activity. Proc. Am. Assoc. Cancer Res., 44: 30, 2003.
20. Solomon, B., Hagekyriakou, J., Trivett, M. K., Stacker, S. A., McArthur, G. A., and Cullinane, C. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int. J. Radiat. Oncol. Biol. Phys., 55: 713-723, 2003.
21. Colquhoun, A. J., Sundar, S., Rajjayabun, P. H., Symonds, R. P., and Mellon, J. K. Can inhibition of epidermal growth factor receptor (EGFR) with gefitinib (ZD1839) improve the response to radiation therapy in bladder cancer? Proc. Am. Soc. Clin. Oncol., 22: 229, 2003.
22. She, Y. H., Lee, F., Chen, J., Haimovitz-Friedman, A., Miller, V. A., Rusch, V. R., Kris, M. G., and Sirotnak, F. M. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates, radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin. Cancer Res., 9: 3773-3778, 2003.
23. Chinnaiyan, P., Huang, S-M., Armstrong, E., and Harari, P. M. Radiosensitization following EGFR signaling inhibition by erlotinib (Tarceva). Int. J. Radiat. Oncol. Biol. Phys., 57 (Suppl. 2): S294, 2003.
24. Raisch, K. P., Russo, S. M., Seay, L. L., Smith, A. C., Iwata, K. K., and Bonner, J. A. EGFr-specific tyrosine kinase inhibitor, erlotinib, in combination with ionizing radiation for the treatment of esophageal carcinoma cells. Clin. Cancer Res., 9: S6104, 2003.
25. Kim, Y-S., Zhou, H., Earp, H. S., and Sartor, C. I. Studies of signaling pathways associated with radiosensitization of EGFR overexpressing breast cancer cells by the dual EGFR/HER2 inhibitor, GW572016. Clin. Cancer Res., 9: S6093, 2003.
26. Natarajan, M., Roldan, F. A., Sheriff, H., Hidalgo, M., Otto, R. A., Herman, T. S., Greenberger, L. M., and Thomas, C. R. EKB-569 attenuates radiation triggered survival response in squamous cell carcinoma. Proc. Am. Soc. Clin. Oncol., 22: 248, 2003.
27. Yarden, Y., and Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol., 2: 127-137, 2001.
28. Harari, P. M. and Huang, S-M. Combining EGFR inhibitor with radiation or chemotherapy: will pre-clinical studies predict clinical results? Int. J. Radiat. Oncol. Biol. Phys., 58: in press, 2004.
29. Harari, P. M., Hartig, G. K., Rischin, D., and Peters, L. J. Promising new approaches in the treatment of advanced head and neck cancer. Am. J. Cancer., 2: 335-347, 2003.
30. Harari, P. M., Huang, S-M., Herbst, R. S., and Quan, H. Molecular targeting of the epidermal growth factor receptor in head and neck cancer. In: L. B. Harrison, R. B. Sessions, and W. K. Hong (eds.), Head and Neck Cancer: A Multidisciplinary Approach, Chapter 41, pp. 1001-1017. Philadelphia: Lippincott Williams & Wilkins, 2003.
31. Giaccone, G., Johnson, D., Scagliotti, G. V., Manegold, C., Rosell, R., Rennie, P., Wolf, M., Averbuch, S., Grous, J., and Fandi, A. Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large Phase III trials (INTACT 1 and 2). Proc. Am. Soc. Clin. Oncol., 22: 627, 2003.
32. Prenzel, N., Fischer, O. M., Streit, S., Hart, S., and Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr.-Relat. Cancer, 8: 11-31, 2001.
33. Grunwald, V., and Hidalgo, M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst. (Bethesda), 95: 851-867, 2003.
34. Zhang, W., Lu, B., Schneider, S., Danenberg, K., Gil, J., Stoehlmacher, J., Ye, W., Groshen, S., Sherrod, A., and Lenz, H-J. Epidermal growth factor receptor (EGFR) gene expression levels and genomic polymorphism predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Proc. Am. Soc. Clin. Oncol., 22: 256, 2003.
35. Oppenheimer, D., Amador, M. L., Embuscando, E., Iacabuzzio-Douanne, C., and Hidalgo, M. Determinants of response to Erlotinib (OSI-774) in head and neck squamous cell carcinoma. Clin. Cancer Res., 9: S6090, 2003.
36. Natale, R. B., Shak, S., Aronson, N., Averbuch, S., Fox, W., Luthringer, D., Clark, K., Baker, J., Cronin, M., and Agus, D. B. Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: predicting response to gefitinib, an EGFR kinase inhibitor. Proc. Am. Soc. Clin. Oncol., 22: 190, 2003.
37. Ciardiello, F., and Tortora, G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur. J. Cancer, 39: 1348-1354, 2003,
38. Amador, M. L., Maitra, A., Gruenwald, V., Peralba, J. M., and Hidalgo, M. Determinants of resistance to OSI-774 in billiary tract carcinoma cell lines. Proc. Am. Soc. Clin. Oncol., 22: 213, 2003.
39. Baker, C. H., Solorzano, C. C., and Fidler, I. J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res., 62: 1996-2003, 2002.
40. Finn, R. S., Wilson, C. A., Sanders, J., Cook, A., Olson, T., Glaspy, P., Tchekmedjian, N., Pegram, M. D., Britten, C., and Slamon, D. J. Targeting the epidermal growth factor receptor (EGFR) and HER-2 with OSI-774 and trastuzumab, respectively, in HER-2 overexpressing human breast cancer cell lines results in a therapeutic advantage in vitro. Proc. Am. Soc. Clin. Oncol., 22: 235, 2003.
41. Kauh, J. S., Laguinge, L., Lin, S., and Jessup, J. M. Combined tyrosine kinase inhibition of c-erb B-2 and EGFR in pancreatic adenocarcinoma leads to increased inhibition of cell growth. Proc. Am. Soc. Clin. Oncol., 22: 876, 2003.
42. Dowlati, A., Nethery, D., Liu, J., and J. A., K. Combined inhibition of epidermal growth factor receptor (EGFR) and JAK/Stat signaling results in superior growth inhibition in A431 cell line as compared to single agent therapy. Proc. Am. Assoc. Cancer Res., 44: 800, 2003.
43. Arteaga, C. L. Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs? Clin Cancer Res., 9: 1231-1232, 2003.
44. Harari, P. M., and Huang, S-M. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin. Radiat. Oncol., 11: 281-289, 2001.